GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (HAM:407) » Definitions » Earnings per Share (Diluted)

Sensei Biotherapeutics (HAM:407) Earnings per Share (Diluted) : €-1.09 (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Earnings per Share (Diluted)?

Sensei Biotherapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2024 was €-0.26. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.09.

Sensei Biotherapeutics's EPS (Basic) for the three months ended in Jun. 2024 was €-0.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.09.

Sensei Biotherapeutics's EPS without NRI for the three months ended in Jun. 2024 was €-0.26. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.09.

During the past 3 years, the average EPS without NRIGrowth Rate was -20.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 32.10% per year.

During the past 6 years, Sensei Biotherapeutics's highest 3-Year average EPS without NRI Growth Rate was 62.00% per year. The lowest was -20.60% per year. And the median was -9.80% per year.


Sensei Biotherapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Sensei Biotherapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Earnings per Share (Diluted) Chart

Sensei Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial -1.50 -0.56 -1.18 -1.49 -1.12

Sensei Biotherapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.26 -0.28 -0.29 -0.26

Competitive Comparison of Sensei Biotherapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, Sensei Biotherapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sensei Biotherapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's PE Ratio falls into.



Sensei Biotherapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Sensei Biotherapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-31.271-0)/27.953
=-1.12

Sensei Biotherapeutics's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2024 is calculated as

Diluted Earnings Per Share (Q: Jun. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-6.635-0)/25.104
=-0.26

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Sensei Biotherapeutics  (HAM:407) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Sensei Biotherapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensei Biotherapeutics Business Description

Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 710, Boston, MA, USA, 02210
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. The company currently has three investigational products. 1) SNS-101 is a conditionally active monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T-cell activation): 2) SNS-102 is a conditionally active monoclonal antibody targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), an immune checkpoint often expressed on macrophages: 3) SNS-103 is a conditionally active monoclonal antibody targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1), also known as CD39.

Sensei Biotherapeutics Headlines

No Headlines